Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocurcumin in Multiple Sclerosis
NCT03150966Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jun 2016
- Primary completion
- Aug 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Nanocurcumin Arm with Placebo Arm (2 arms). Primary endpoint: Expanded Disability Status Scale at 6 months. Started Jun 2016; status: completed.
02
Drugs
nanocurcumin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03150966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150966.